{"id":7511,"date":"2022-12-27T19:04:30","date_gmt":"2022-12-27T18:04:30","guid":{"rendered":"https:\/\/www.ab-science.com\/?p=7511"},"modified":"2022-12-27T19:06:41","modified_gmt":"2022-12-27T18:06:41","slug":"le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse","status":"publish","type":"post","link":"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/","title":{"rendered":"Le masitinib re\u00e7oit la d\u00e9signation de m\u00e9dicament orphelin pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique en Suisse"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text]<\/p>\n<h3 class=\"Default\">27\/12\/2022 \u2013\u00a0AB Science annonce aujourd&rsquo;hui que le masitinib a re\u00e7u la d\u00e9signation de m\u00e9dicament orphelin (ODS) par l&rsquo;Institut Suisse des Produits Th\u00e9rapeutiques (Swissmedic) pour le traitement des patients atteints de scl\u00e9rose lat\u00e9rale amyotrophique (SLA)<\/h3>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<iframe width=\"100%\" height=\"800\" src=\"https:\/\/www.ab-science.com\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL3d3dy5hYi1zY2llbmNlLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyMi8xMi9DUC1BTFMtU3dpc3NtZWRpYy1PREQtVkZSLVZGLnBkZiZzZXR0aW5ncz0xMTEwMTExMTExMTExMTExMTAwJmxhbmc9ZW4tVVM=#page=&zoom=100&pagemode=none\" title=\"\"><\/iframe>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">#default-btn-cf4ccce113ce2472756286db2f603cc9.ico-right-side > i {\n  margin-right: 0px;\n  margin-left: 8px;\n}\n#default-btn-cf4ccce113ce2472756286db2f603cc9 > i {\n  margin-right: 8px;\n}<\/style><div class=\"btn-align-center\"><a href=\"https:\/\/www.ab-science.com\/wp-content\/uploads\/2022\/12\/CP-ALS-Swissmedic-ODD-VFR-VF.pdf\" class=\"default-btn-shortcode dt-btn dt-btn-l link-hover-off  vc_custom_1672164188025\" target=\"_blank\" id=\"default-btn-cf4ccce113ce2472756286db2f603cc9\" rel=\"noopener\"><i class=\"dt-icon-the7-download\"><\/i><span>T\u00e9l\u00e9charger le PDF<\/span><\/a><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text] 27\/12\/2022 \u2013\u00a0AB Science annonce aujourd&rsquo;hui que le masitinib a re\u00e7u la d\u00e9signation de m\u00e9dicament orphelin (ODS) par l&rsquo;Institut Suisse des Produits Th\u00e9rapeutiques (Swissmedic) pour le traitement des patients atteints de scl\u00e9rose lat\u00e9rale amyotrophique (SLA) [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[],"class_list":["post-7511","post","type-post","status-publish","format-standard","hentry","category-2022-fr","category-127","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Le masitinib re\u00e7oit la d\u00e9signation de m\u00e9dicament orphelin pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique en Suisse<\/title>\n<meta name=\"description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Le masitinib re\u00e7oit la d\u00e9signation de m\u00e9dicament orphelin pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique en Suisse\" \/>\n<meta property=\"og:description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-27T18:04:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-27T18:06:41+00:00\" \/>\n<meta name=\"author\" content=\"Alexis BERNARD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis BERNARD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\\\/\"},\"author\":{\"name\":\"Alexis BERNARD\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\"},\"headline\":\"Le masitinib re\u00e7oit la d\u00e9signation de m\u00e9dicament orphelin pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique en Suisse\",\"datePublished\":\"2022-12-27T18:04:30+00:00\",\"dateModified\":\"2022-12-27T18:06:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\\\/\"},\"wordCount\":161,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"articleSection\":[\"2022\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\\\/\",\"name\":\"Le masitinib re\u00e7oit la d\u00e9signation de m\u00e9dicament orphelin pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique en Suisse\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-12-27T18:04:30+00:00\",\"dateModified\":\"2022-12-27T18:06:41+00:00\",\"description\":\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Le masitinib re\u00e7oit la d\u00e9signation de m\u00e9dicament orphelin pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique en Suisse\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\",\"name\":\"Alexis BERNARD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"caption\":\"Alexis BERNARD\"},\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/author\\\/abernard\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Le masitinib re\u00e7oit la d\u00e9signation de m\u00e9dicament orphelin pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique en Suisse","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/","og_locale":"fr_FR","og_type":"article","og_title":"Le masitinib re\u00e7oit la d\u00e9signation de m\u00e9dicament orphelin pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique en Suisse","og_description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","og_url":"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/","og_site_name":"AB Science","article_published_time":"2022-12-27T18:04:30+00:00","article_modified_time":"2022-12-27T18:06:41+00:00","author":"Alexis BERNARD","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Alexis BERNARD","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/#article","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/"},"author":{"name":"Alexis BERNARD","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755"},"headline":"Le masitinib re\u00e7oit la d\u00e9signation de m\u00e9dicament orphelin pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique en Suisse","datePublished":"2022-12-27T18:04:30+00:00","dateModified":"2022-12-27T18:06:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/"},"wordCount":161,"publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"articleSection":["2022"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/","url":"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/","name":"Le masitinib re\u00e7oit la d\u00e9signation de m\u00e9dicament orphelin pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique en Suisse","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2022-12-27T18:04:30+00:00","dateModified":"2022-12-27T18:06:41+00:00","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/le-masitinib-recoit-la-designation-de-medicament-orphelin-pour-le-traitement-de-la-sclerose-laterale-amyotrophique-en-suisse\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Le masitinib re\u00e7oit la d\u00e9signation de m\u00e9dicament orphelin pour le traitement de la scl\u00e9rose lat\u00e9rale amyotrophique en Suisse"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]},{"@type":"Person","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755","name":"Alexis BERNARD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","caption":"Alexis BERNARD"},"url":"https:\/\/www.ab-science.com\/fr\/author\/abernard\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/7511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=7511"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/7511\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=7511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/categories?post=7511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/tags?post=7511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}